Novartis data show psoriasis patients treated with Cosentyx® reported improvements in quality of life measures as early as Week 4
EAST HANOVER, N.J., Jan. 28, 2019 /PRNewswire/ -- Novartis announced today results from a pooled analysis of four Phase 3 clinical trials demonstrating patients with moderate-to-severe plaque psoriasis (PsO) treated with Cosentyx(®) (secukinumab) 300 mg reported improvements in mobility, self-care, and usual activities components of the EQ-5D-3L questionnaire as early as Week 4 when compared to placebo in patients who reported problems at baseline.(1) The results were presented at the 15(th) Annual Maui Derm for Dermatologists 2019.
"Moderate-to-severe plaque psoriasis can impact every aspect of a person's life," stated Steven R. Feldman, M.D., Ph.D, Wake Forest School of Medicine*. "These findings suggest that helping patients feel better through improved quality of life and ability to function should be a goal as important as skin clearance in psoriasis management."
Plaque psoriasis is characterized by painful red, raised, dry patches of skin usually covered by silvery or white scales.(2) The disease typically involves the extensor areas of the forearms and shins, along with hard-to-treat areas like the scalp, palms of the hand, soles of the feet and finger nails.(2,3) Many patients with psoriasis also live with concurrent psoriatic arthritis (PsA), an inflammatory form of arthritis causing stiffness, pain, and swelling in the joints. When left untreated, PsA can cause irreversible joint damage and lead to physical limitations.(4) For patients experiencing symptoms of PsO and PsA the physical limitations can lead to psychological problems that can affect every day social activities and work causing embarrassment, lack of self-esteem, anxiety and depression.(2,4-5)
The pooled analysis of the ERASURE, FIXTURE, FEATURE, and JUNCTURE trials included patients with moderate-to-severe plaque psoriasis who were randomized to receive placebo or Cosentyx 300 mg and who reported problems with mobility, self-care, or usual activities (e.g. work, study, housework, family or leisure activities) at baseline, as recorded by the EQ-5D questionnaire. The percentages of patients reporting problems in the EQ-5D-3L mobility, self-care, or usual activities domains were compared at weeks 4, 8, and 12 between patients receiving placebo (n=282) and Cosentyx 300 mg (n=309).(1)
-- Change in Mobility: The percentage of patients reporting no problems in
mobility at Week 4 was higher with Cosentyx 300 mg compared with placebo
(60.7% vs 38.5%); similar trends were observed at Weeks 8 (73.6% vs
48.1%) and 12 (71.4% vs 46.6%).(1)
-- Change in Self Care: The percentage of patients reporting no problems in
self-care at Week 4 was higher with Cosentyx 300 mg compared with
placebo (71.4% vs 40.9%); similar trends were observed at Weeks 8 (79.2%
vs 42.3%) and 12 (87.1% vs 43.0%).(1)
-- Change in Usual Activities: The percentage of patients reporting no
problems in usual activities at Week 4 was twice higher with Cosentyx
300 mg compared with placebo (63.8% vs 31.1%); similar trends were
observed at Weeks 8 (74.4% vs 35.7%) and 12 (82.7% vs 42.6%).(1)
Cosentyx is the first and only fully human IL-17A antagonist approved to treat moderate to severe plaque psoriasis, psoriatic arthritis (PsA), and ankylosing spondylitis (AS).(6) To date, over 14,630 unique prescribers have experience with Cosentyx, and have prescribed Cosentyx to more than 105,000 US patients to date across all indications.(7)
About Cosentyx (secukinumab) and IL-17A
Cosentyx, launched in 2015, is the first and only fully-human interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS).(6) By specifically targeting IL-17A, Cosentyx addresses an important cytokine involved in the development of psoriasis.(6,8) IL-17A plays an important role in the pathogenesis of plaque psoriasis, PsA and AS.(8-10) Up to 30% of patients with psoriasis may have PsA.(11-12)
In psoriasis, Cosentyx delivers long-lasting skin clearance with a sustained response and favorable safety profile out to 5 years, as demonstrated in a clinical study, along with convenient dosing in a patient-friendly auto injector.(13,14) Cosentyx has been studied in dedicated trials for the most difficult-to-treat types of plaque psoriasis - palmoplantar psoriasis (psoriasis of the hands and feet), scalp psoriasis, and nail psoriasis.(15-17)
Cosentyx is approved in more than 75 countries for the treatment of moderate to severe plaque psoriasis, which includes the European Union countries, Japan, Switzerland, Australia, the US and Canada. In Europe, Cosentyx is approved for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.(18 )In the US, Cosentyx is approved as a treatment for moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy (light therapy).(6)
In addition, Cosentyx is the first IL-17A antagonist approved in more than 65 countries for the treatment of active AS and PsA, which includes the European Union countries and the US. Cosentyx is also approved for the treatment of PsA and pustular psoriasis in Japan.(19)
About the Pooled Analysis(1
)This pooled analysis of four phase 3 clinical trials (ERASURE, FIXTURE, FEATURE, and JUNCTURE) included patients with moderate-to-severe psoriasis who were randomized to receive placebo or Cosentyx (Secukinumab) 300 mg and who reported problems with mobility, self-care, or usual activities at baseline. Demographic characteristics (age, sex, race, and body weight), treatment history, and clinical characteristics (body surface area [BSA]; Dermatology Life Quality Index [DLQI]; mobility, self-care, and usual activities domains of the EQ-5D-3L; Psoriasis Area and Severity Index [PASI]; and concurrent PsA [30.1% of patients in placebo arm and 25.9% of patients in Cosentyx 300 mg arm]) were examined at baseline. The EQ-5D-3L is a general health instrument with 5 domains (mobility, self-care, usual activities [eg, work, study, housework, family or leisure activities], pain/discomfort, and anxiety/depression), each scored at 3 levels. For the purpose of this study, "some problems" and "extreme problems" were grouped as "any problems," resulting in scoring at 2 levels. The percentages of patients reporting problems in the EQ-5D-3L mobility, self-care, or usual activities domains were compared at Weeks 4, 8, and 12 between patients receiving placebo and those receiving Cosentyx 300 mg.
About psoriasis
Psoriasis is a common, non-contagious, auto-immune disease that affects more than 125 million people worldwide.(2,20) Plaque psoriasis is the most common form of the disease and appears as raised, red patches covered with a silvery white build-up of dead skin cells.(2)
Psoriasis is not simply a cosmetic problem, but a persistent, chronic (long-lasting), and sometimes distressing disease, which can affect even the smallest aspects of people's lives on a daily basis.(2) Up to 30% of patients with psoriasis may have PsA.(11-12 )PsA is a condition in which the joints are also affected, causing debilitating symptoms including pain, stiffness and for some people, irreversible joint damage.(4 )Psoriasis is also associated with other serious health conditions, such as diabetes, heart disease and depression.(2)
INDICATIONS
Cosentyx is a human interleukin-17A antagonist indicated for the treatment of:
-- moderate to severe plaque psoriasis in adult patients who are candidates
for systemic therapy or phototherapy
-- adults with active psoriatic arthritis (PsA)
-- adults with active ankylosing spondylitis (AS)
IMPORTANT SAFETY INFORMATION
Do not use Cosentyx if you have had a severe allergic reaction to secukinumab or any of the other ingredients in Cosentyx. See the Medication Guide for a complete list of ingredients.
Cosentyx is a medicine that affects your immune system. Cosentyx may increase your risk of having serious side effects such as:
Infections
Cosentyx may lower the ability of your immune system to fight infections and may increase your risk of infections.
-- Your doctor should check you for tuberculosis (TB) before starting
treatment with Cosentyx.
-- If your doctor feels that you are at risk for TB, you may be treated
with medicine for TB before you begin treatment with Cosentyx and during
treatment with Cosentyx.
-- Your doctor should watch you closely for signs and symptoms of TB during
treatment with Cosentyx. Do not take Cosentyx if you have an active TB
infection.
Before starting Cosentyx, tell your doctor if you:
-- are being treated for an infection
-- have an infection that does not go away or that keeps
coming back
-- have TB or have been in close contact with someone with
TB
-- think you have an infection or have symptoms of an
infection such as:
o fevers, sweats, or chills
o warm, red, or painful skin or
sores on your body
o muscle aches
o diarrhea or stomach pain
o burning when you urinate
o cough
or urinate more often than
normal
o shortness of breath
o blood in your phlegm
o weight loss
After starting Cosentyx, call your doctor right away if you have any signs of infection listed above. Do not use Cosentyx if you have any signs of infection unless you are instructed to by your doctor.
Inflammatory Bowel Disease
New cases of inflammatory bowel disease or "flare-ups" can happen with Cosentyx, and can sometimes be serious. If you have inflammatory bowel disease (ulcerative colitis or Crohn's disease), tell your doctor if you have worsening disease symptoms during treatment with Cosentyx or develop new symptoms of stomach pain or diarrhea.
Serious Allergic Reactions
Serious allergic reactions can occur. Get emergency medical help right away if you get any of the following symptoms: feeling faint; swelling of your face, eyelids, lips, mouth, tongue, or throat; trouble breathing or throat tightness; chest tightness; or skin rash. If you have a severe allergic reaction, do not give another injection of Cosentyx.
Before starting Cosentyx, tell your doctor if you:
-- have any of the conditions or symptoms listed above for infections
-- have inflammatory bowel disease (Crohn's disease or ulcerative colitis)
-- are allergic to latex. The needle caps contain latex.
-- have recently received or are scheduled to receive an immunization
(vaccine). People who take Cosentyx should not receive live vaccines.
-- have any other medical conditions
-- are pregnant or plan to become pregnant. It is not known if Cosentyx can
harm your unborn baby. You and your doctor should decide if you will use
Cosentyx.
-- are breastfeeding or plan to breastfeed. It is not known if Cosentyx
passes into your breast milk.
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of your medicines to show your doctor and pharmacist when you get a new medicine.
How should I use Cosentyx?
See the detailed Instructions for Use that comes with your Cosentyx for information on how to prepare and inject a dose of Cosentyx, and how to properly throw away (dispose of) used Cosentyx Sensoready® pens and prefilled syringes.
-- Use Cosentyx exactly as prescribed by your doctor.
-- If your doctor decides that you or a caregiver may give your injections
of Cosentyx at home, you should receive training on the right way to
prepare and inject Cosentyx. Do not try to inject Cosentyx yourself,
until you or your caregiver has been shown how to inject Cosentyx by
your doctor or nurse.
The most common side effects of Cosentyx include: cold symptoms, diarrhea, and upper respiratory infections. These are not all of the possible side effects of Cosentyx. Call your doctor for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please see accompanying full Prescribing Information, including Medication Guide.
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; general economic and industry conditions, including the effects of the persistently weak economic and financial environment in many countries; safety, quality or manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Located in East Hanover, NJ Novartis Pharmaceuticals Corporation is an affiliate of Novartis which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 121,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com
References:
1. Feldman SR, Gomez B, Meng X, et al. Secukinumab Rapidly Improves Mobility, Self-Care, and Usual Activities in Patients With Psoriasis: Pooled Analysis From Four Phase 3 Trials. Poster presented at Maui Derm for Dermatologists 2019; January 26-30,
2019, Maui, Hawaii, USA.
2.
Global Report on Psoriasis. World Health Organization. http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf. Published 2016. Accessed January 2, 2019.
3.
Baran R. The burden of nail psoriasis: an introduction. Dermatol. 2010:221 Suppl 1:1-5.
4.
Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74:423-441.
5.
Husni ME et al. The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum.2017;7: 351-360
6.
Cosentyx [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.
7.
Novartis Data on File. U.S. Prescriber and Patient Counts. Novartis Pharmaceuticals Corp; Nov. 2018.
8.
Zeichner J, Armstrong A. The Role of IL-17 in the Pathogenesis and Treatment of Psoriasis. J Clin Aesthetic Dermatol. 2016 9(6 Suppl 1):S3-S6 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395242/.
9.
Barker J, Kaplan DH, Nestle FO, Psoriasis. N Engl J Med. 2009;361:496-509. http://www.nejm.org/doi/full/10.1056/NEJMra0804595#t=article.
10.
Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167:717-24. 2019.
11.
Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5): 729-735.
12.
Alinaghi F, Calov M, Kristensen LE, et. al., Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. JAAD. 2018; 1-33.
13.
Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favorable safety profile through 5 years of treatment in moderate to severe psoriasis. JEADV.2018;32:1507-1514.
14. Lacour JP, Paul C, Jazayeri S, et al. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol. 2017;31(5):847-856.
15. Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis. ClinicalTrials.gov.https://clinicaltrials.gov/ct2/show/
NCT01806597?term=secukinumab&cond=palmoplantar%2Bpsoriasis&cntry1=NA%3AUS&rank=1. Published March 7, 2013. Accessed January 2, 2018.
16. Study of, Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02267135?term=Scalp&cond=secukinumab&rank=1. Published October 17, 2014.
Accessed January 2, 2018.
17. Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis.ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01807520?term=secukinumab&draw=4&rank=13. Published March 8, 2013. Accessed
January 2, 2018.
18. European Medicines Agency. Cosentyx Summary of Product Characteristics. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003729/human_med_001832.jsp&mid=WC0b01ac058001d124. Updated July 17, 2017. Accessed January
2018.
19.
Pharmaceuticals and Medical Devices Agency. Review Report. Pharmaceuticals and Medical Devices Agency http://www.pmda.go.jp/files/000216877.pdf. Published November 12, 2015. Accessed January 2, 2019.
20.
Profile of Psoriasis. International Federation of Psoriasis Associations. http://www.worldpsoriasisday.com/web/page.aspx?refid=114. Published March 1, 2016. Accessed January 2, 2019.
*
S. R. Feldman's disclosure: S. R. Feldman has received consulting, speaking, and/or research support from Novartis, AbbVie, Celgene, Sun Pharma, Janssen, Lilly, and Ortho.
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com
Eric Althoff
Jeannie Neufeld
Novartis Global Media
Relations
Novartis Pharmaceuticals Corporation
+41 61 324 7999 (direct)
+1 862 778 2104 (direct)
+41 79 593 4202 (mobile)
+1 201 650 2728 (mobile)
eric.althoff@novartis.com
jeannie.neufeld@novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel
Bringer +41 61 324 1065
Cory Twining +1 212 830 2417
Thomas
Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
1/19 COS-1369814
View original content:http://www.prnewswire.com/news-releases/novartis-data-show-psoriasis-patients-treated-with-cosentyx-reported-improvements-in-quality-of-life-measures-as-early-as-week-4-300784847.html
SOURCE Novartis Pharmaceuticals Corporation
